From ShigOraVax to ShigaPlexIM
The original plans of the project were based on a tetravalent whole cell inactivated oral Shigella vaccine ‘ShigOraVax’, containing Shigella flexneri serotypes 2a, 3a, and 6, as well as Shigella sonnei. It was planned to develop the proposed Shigella vaccine candidate up to mid clinical stage.
In the year 2021, the original plans have changed as the ‘ShigOraVax’ vaccine will not be available and a new candidate vaccine was identified to replace the original candidate vaccine and the project was renamed ShigaPlexIM.
ShigaPlexIM Kick-off meeting was held virtually on 7 July 2022.